Clinical Trials

Clinical trials are a necessary part of the process of developing new approaches to treating retinal conditions and help us understand retinal diseases more thoroughly. The specific trials we are conducting change regularly, but are all focused on optimizing outcomes for patients with retinal diseases. There are many potential benefits to participating in a clinical trial, including helping to advance the field of retinal diseases which include the most common causes of blindness in the USA and most developed countries around the world. Each clinical study has specific criteria that participants must meet. If you’re interested in participating in a clinical trial, please ask your doctor


Ongoing Clinical Trials


Wet Age-Related Macular Degeneration


NCT03150589: SB11-G31-AMD

A Phase III Randomized, Double-masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB11 and Lucentis® in Subjects With Neovascular Age-related Macular Degeneration


NCT03345082: OPT-302-1002

A Phase II Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration


NCT03539549: Maple

Phase II Study Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD)


NCT 02462928: Cedar

A Phase III Safety and Efficacy Study of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration


NCT 03465709: Furlong

A Phase Ib/II, 18-Month, Multi-Center, Open Label Study to Evaluate the Safety of Intravitreal APL-2 Therapy in Patients With Neovascular Age-Related Macular Degeneration (AMD)


Dry Age-Related Macular Degeneration


NCT02686658: OPH2003

A Phase II/III Randomized, Double Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration


NCT 02462889: Pro-Con

Phase II, Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) Versus Sham as PROphylaxis Against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes


Diabetic Retinopathy

NCT 02863354: Recovery

Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy


NCT 03197870: Time2B

Phase II, Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy


NCT unavailable: Protocol AA

Peripheral Diabetic Retinopathy (DR)Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time


NCT 01909791: Protocol V

Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity


NCT 02634333: Protocol W

Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk


NCT 02718326: Panorama

A Phase III, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy


Retinal Vein Occlusion

Coming Soon!